Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.

Germany's MediGene has signed yet another agreement for its treatment for genital warts, Veregen ointment (previously Polyphenon E), the latest deal being with Serbian company, Pharmanova, which will supply and commercialise the product in South-eastern Europe. The territories covered by the agreement include Serbia, Bosnia and Herzegovina, Montenegro, Macedonia, Croatia, Slovenia, and Albania.

The German biotech company MediGene has signed another licence and supply agreement for the commercialisation and marketing of Veregen (previously Polyphenon E) ointment for the treatment of genital warts, this time with SynCore Biotechnology in Taiwan.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.